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Abstract
Background: Transmission-blocking vaccines (TBVs) have been considered an important strategy for disrupting the
malaria transmission cycle, especially for Plasmodium vivax malaria, which undergoes gametocytogenesis earlier
during infection. Pvs25 and Pvs28 are transmission-blocking vaccine candidates for P. vivax malaria. Assessment of
genetic diversity of the vaccine candidates will provide necessary information for predicting the performance of
vaccines, which will guide us during the development of malaria vaccines.
Results: We sequenced the coding regions of pvs25 and pvs28 from 30 P. vivax isolates from Yunnan Province,
identifying five amino acid haplotypes of Pvs25 and seven amino acid haplotypes of Pvs28. Among a total of four
mutant residues, the predominant haplotype of Pvs25 only had the I130T substitution. For Pvs28, a total of eight
amino acid substitutions were identified. The predominant haplotype of Pvs28 had two substitution at positions 52
(M52L) and 140 (T140S) with 5-6 GSGGE/D tandem repeats at the end of fourth EGF-like domain. Most amino acid
substitutions were common with previous reports from South Asian isolates. Although the nucleotide diversity of
pvs28 (π = 0.0034 ± 0.0012) was significantly higher than pvs25 (π = 0.0013 ± 0.0009), it was still conserved when
compared with the blood stage vaccine candidates.
Conclusions: Genetic analysis revealed limited genetic diversity of pvs25 and pvs28, suggesting antigenic diversity
may not be a particular problem for Sal I based TBVs in most P. vivax-endemic areas of China.
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Background
Plasmodium vivax, the most widespread species of
human malaria parasites, is responsible for the majority
of malaria cases outside of Africa, and the most prevalent
form of relapsing malaria. Although not as lethal as
P. falciparum malaria, P. vivax has caused substantial
morbidity for human populations residing in Asia and
South America [1,2]. Throughout the malaria control his-
tory, P. vivax malaria has displayed tremendous resilience
to control efforts, which is in part due to two biological
characteristics of this parasite. One is the formation of
hypnozoites in the liver, which is responsible for relapses
of the disease. The other is that P. vivax undergoes game-
tocytogenesis before manifestation of the disease symp-
toms, making transmission possible before treatment.
P. vivax is the predominant Plasmodium species in
China, and in recent years, P. vivax cases accounted for
more than 90% of all malaria cases [3]. As The Ministry
of Health of China has set the goal of malaria elimination
by 2020 [4], interruption of vivax malaria transmission is
a major challenge. Yunnan is one of the two provinces
that have year-round local transmission of P. vivax and
P. falciparum. It is located in southwest China and bor-
ders Myanmar to the west and Laos and Vietnam to the
south [5]. A total of 250,070 confirmed cases of P. vivax
malaria and 44,465 cases of P. falciparum malaria have
been reported between 1991 and 2006 in Yunnan [6]. In
recent years, we have witnessed a significant decline of
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malaria cases in Yunnan [3]. A total of 32,566 confirmed
cases of P. vivax malaria and 5,821 cases of P. falciparum
malaria have been reported between 2006 and 2009 in
Yunnan [3,7-9]. Most of the malaria cases are now clus-
tered in counties located at the China-Myanmar border
area [3,10]. Despite improvement in malaria situation in
this region, malaria control along the borders is proble-
matic, since reintroduction of malaria by human migra-
tion is still difficult to monitor. Thus, it is particularly
important to develop effective strategies to control and
eliminate malaria in this region.
Transmission-blocking vaccines (TBVs), which target
the sexual stages of malaria parasites to prevent their
further development within mosquitoes, are considered an
important strategy for disrupting malaria transmission
[11,12]. To date, several sexual stage antigens have been
characterized, which showed excellent transmission block-
ing activities. These include the pre-fertilization antigens
P48/45 and post-fertilization antigens P25 and P28. P25
and P28, are specifically expressed on Plasmodium zygote
and ookinete surface [11], and they are essential for the
survival of ookinetes in the mosquito midgut, and sub-
sequent penetration of the midgut epithelium and trans-
formation into oocysts [13]. Among the TBVs candidates,
Pvs25 has received the most attention. Recombinant Pvs25
protein expressed in bacteria [14], yeasts [15,16] and bacu-
lovirus [17] exhibits strong immunogenicity and immune
sera display significant transmission-blocking activity on
the development of sporozoites [14] and oocysts [15-17].
The immunogenicity trials of recombinant Pvs25 have
been undertaken in rhesus monkeys [18] and human
volunteers [19,20]. A phase I clinical trial of Pvs25H vac-
cine in human volunteers has demonstrated that vaccine-
induced antibodies have significant transmission-blocking
activity [19]. It has been reported that antisera to recombi-
nant Pvs25 and Pvs28 based on the Sal-I strain recognized
the corresponding molecules expressed by field-isolated
parasites in Thailand, and that these antisera blocked
transmission of field isolates [15].
Polymorphisms represent a major impediment in vac-
cine design. An effective vaccine must either be based on
conserved regions or incorporate multiple allelic forms of
the antigen. As antigenic polymorphisms limit the immu-
nogenicity and immunoreactivity of vaccines, it is neces-
sary to understand antigenic variations in order to
generate effective vaccines against natural Plasmodium
infections [12]. Pvs25 and Pvs28 contained conserved
structures, which are characterized by a secretory N-
terminal signal sequence followed by four epidermal
growth factor (EGF) domains and a glycosylphosphatidy-
linositol (GPI) anchor [21]. To date, genetic diversity of
pvs25 and pvs28 genes has been surveyed in several
Asian countries, including South Korea [22], Indonesia
[23], Iran [24], India [25,26], Bangladesh [25], and
Thailand [15]. In this study, we aim to analyze the
genetic diversity of these candidate TBVs genes in para-
site isolates from Yunnan Province, China.
Methods
Study areas
Yunnan Province is one of the most highly endemic
regions in China with year-round transmission of
P. vivax and P. falciparum. Since 2001, there has been a
strong seasonal pattern of malaria incidence character-
ized by a peak of infection occurring from June to July
and another peak from October to November [27].
Counties with higher malaria incidence rates are clus-
tered in the border area and the Yuanjiang River Basin
[6,27]. The predominant malaria vectors are Anopheles
minimus and Anopheles dirus [28].
Parasite collection
A total of 30 parasite samples were collected in 2004
from three regions in Yunnan. All volunteers in this
study were symptomatic patients diagnosed with
P. vivax malaria using Giemsa stained thin smear exami-
nation by malaria clinic staff. After informed consent/
assent was obtained from either adults or parents or
legal guardians of children, ~100 μl of finger-prick
blood were collected from each patient on filter papers.
The patients were Yunnan local residents, 13 to 50
years old, living in Baoshan (10 individuals), Ruili (10
individuals) and Longchuan (10 individuals) (showed in
Figure 1). Patients were then treated according to the
Ministry of Health drug policy. This study protocol was
approved by the Biomedical Research Ethics Review
Board at China Medical University.
Parasite DNA preparation and amplification
Three circles, 2.5 mm in diameter, were punched out from
each dried blood spot and Plasmodium DNA was purified
using the QIAamp DNA Mini kit (QIAGEN, Hilden, Ger-
many) according to the manufacturer’s protocol. DNA
was eluted in 60 μl of H2O. pvs25 (GenBank: AF083502.1)
and pvs28 (GenBank: AF083503.2) of the Salvador I (Sal I)
strain were used as reference sequences. The full-length
open reading frames (ORFs) of pvs25 and pvs28 were
amplified using the following primer pairs: pvs25F (5’-
CACTTAGCCAAAATGAACTC-3’) and pvs25 R (5’-
AAAGGACAAGCAGGATGATA-3’) for pvs25; pvs28F
(5’-CTACCACAGCTTGCTGTTCC-3’) and pvs28R (5’-
TGACATCATGAAGAAGGCG-3’) for pvs28. The PCR
reaction contained 2 μl of 10 × KOD-Plus buffer, 2 μl of
2 mM dNTPs, 0.8 μl of 25 mM MgSO4, 1.0 μl of 10 μM of
each primer, 0.2 units of KOD-Plus DNA polymerase
(Toyobo, Osaka, Japan), and 0.5 μl genomic DNA template
in a final volume of 20 μl. Amplification conditions were
as follows: initial denaturing at 94°C for 2 min, 35 cycles
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of 94°C for 15 sec, 56°C (for pvs28) or 54°C (for pvs25) for
15 sec, and 68°C for 1 min, and a final extension at 68°C
for 5 min. PCR products were cleaned up using Exonu-
clease I and Shrip alkaline phosphatase treatment accord-
ing to the manufacturer’s instructions (USB, CA, USA).
DNA sequencing
Pvs25 and pvs28 ORFs were sequenced using the ABI
Prism® BigDye™ Terminator cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) on an ABI
PRISM® 310 Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA, USA). Sequencing primers are: pvs25F (5’-
GAAACCCTAGGCAAAGCATG-3’) and pvs25R (5’- GG
GACTTTGCCA ATAGCACA-3’) for pvs25, and pvs28F
(5’-AACTGTGGAGACTACGCTG-3’) and pvs28R (5’-
ATATTACAAGAGCACATGGTG-3’) for pvs28.
Statistical Analysis
The ORFs of pvs25 and pvs28 were aligned with the
reference sequences using the CLUSTAL W program
[29] with manual corrections. Nucleotide diversity (π)
and its standard error (SE) were calculated with the
Jukes and Cantor method using MEGA 4.0. The number
of haplotypes (h), haplotypes diversity (Hd), segregating
sites (S) were computed using the options available in
DnaSP 5.0 [30].
Results
Sequence polymorphisms of the pvs25 and pvs28 genes
Pvs25 and pvs28 genes were successfully amplified in 30
P. vivax samples obtained from Yunnan. The sequence
of pvs25 (645 bp) and pvs28 (712 bp) were determined
by direct sequencing of the PCR products. The 30 pvs25
sequences contained four polymorphic nucleotide sites
(C103A, G289C, T389C, and C391A), which resulted in
four amino acid substitutions (L35M, E97Q, I130T, and
Q131K). These substitutions resulted in a total of five
amino acid haplotypes, hitherto referred to as Pvs25-I,
II, III, IV and V (Table 1). The predominant amino acid
haplotype of Pvs25 only had the I130T substitution.
Figure 1 Map of the Yunnan Province of China to show the sampling sites.
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The 30 pvs28 sequences had nucleotide polymorphisms
at 13 sites, which included four synonymous substitutions
(T346C, T558C, C573T, and G579A) and eight nonsynon-
ymous substitutions (G40T, A154C, T292A, G313A,
T346G, C419G, G536A, and C666G), which resulted in
eight amino acid substitutions (V14L, M52L, L98I, E105K,
L116V, T140S, G179E, and I222M). A total of seven
amino acid haplotypes were identified: Pvs28-I, II, III, IV,
V, VI and VII (Table 2). The predominant amino acid
haplotype of Pvs28 had two amino acid substitutions at
positions 52 (M52L) and 140 (T140S). Compared with
Sal-I strain, we found the majority of clones had six copies
of GSGGE/D tandem repeats at the end of fourth EGF-
like domain. Only one clone with Pvs28-I haplotype had
five copies of repeat regions.
Compared with the worldwide isolates
Compared with previous reports of worldwide isolates,
Pvs25-I haplotype showed 100% identity with isolates
from Vietnam (GenBank: ABG29072.1), North Korea
(GenBank: AAV33640.1) [23], Thailand (GenBank:
AB091730.1) [15] and Mexico (GenBank: ABS70906.1-
ABS70935.1) [31]. The Pvs25-II haplotype was similar to
some isolates from Bangladesh (GenBank: BAA94348.1-
BAA94350.1) [25] and Thailand (GenBank: BAC66001.1)
[15]. The Pvs25-III haplotype was common with isolates
from Iran (GenBank: ACJ54129.1, ACJ54128.1) [24], Thai-
land (GenBank: BAC66003.1) [15], Indonesia (GenBank:
AAV33639.1) [23], India (GenBank: BAA94346.1) [25] and
Bangladesh (GenBank: BAA94347.1) [25]. Only Pvs25-IV
was unique in China. Like in some South Korean isolates,
position 35 was also polymorphic, but the substitution is
L35M in the Yunnan isolate as compared to L35P in
South Korean isolates (GenBank: ADJ18839.1) [22].
The Pvs28-I haplotype in Yunnan isolates was also com-
mon in isolates from Iran (GenBank: ACJ54136.1) [24]
and Bangladesh (GenBank: BAA94352.1, BAA94353.1,
BAA94371.1, BAA94362, BAA94363) [25]. The Pvs28-
II haplotype was similar with those from Thailand (Gen-
Bank: BAC66011.1) [15] and Bangladesh (GenBank:
BAA94370.1, BAA94369.1) [25]. Parasite isolates from
Yunnan contained some region-specific haplotypes. Hap-
lotype Pvs28-III with a new V14L substitution was found
only in one isolate. The remaining haplotypes (Pvs28-IV,
V and VI) were only identified in the Yunnan isolates. The
G179E mutation was only found in South Korean (Gen-
Bank: ADJ18881.1) [22] and Chinese isolates.
The Pvs25 and Pvs28 amino acid substitutions identi-
fied from worldwide isolates including those from China
are summarized in Tables 3 and 4. Among a total of 17
variant amino acids in Pvs25 from worldwide isolates,
I130T was the most common amino acid substitution
from American and Asian isolates. The Q87K substitu-
tion was common in American isolates such as those
from Brazil [23] and Mexico [31], and Western Asian iso-
lates such as those from Iran [24] and Turkey, but not
detected in South and East Asian isolates. Amino acid
residue E97Q was detected in some Asian isolates such
as those from Iran [24], Bangladesh [25], Thailand [15],
India [25,26], Indonesia [23], South Korea [22], Central
China [32] and Yunnan, but rare in American isolates.
Compared with previous studies from Central China iso-
lates, amino acid residue I130T was the major amino
acid substitution in Yunnan, Zhejiang and Hubei isolates
[32]. The amino acid residue Q131K was not detected in
Table 1 Amino acid substitutions of Pvs25 from Yunnan
P. vivax isolates
Haplotypes (number) EGF-1 EGF-2 EGF-3 EGF-3
35 97 130 131
Sal-I L E I Q
Pvs25-I (n = 15) • • T •
Pvs25-II (n = 8) • • T K
Pvs25-III (n = 5) • Q T •
Pvs25-IV (n = 1) • Q T K
Pvs25-V (n = 1) M • T K
EGF, epidermal growth factor-like domain. • indicates identical amino acid
residues compared to the Salvador I strain.
Table 2 Amino acid substitutions of Pvs28 from Yunnan P. vivax isolates
Haplotypes (number) SS EGF-1 EGF-2 EGF-2 EGF-3 EGF-3 RR RR THR
14 52 98 105 116 140 179 # 222
Sal-I V M L E L T G 6 I
Pvs28-I (n = 19) • L • • • S • 5/6 •
Pvs28-II (n = 4) • • I • V • • 6 •
Pvs28-III (n = 2) L • • K V • • 6 •
Pvs28-IV (n = 2) • L • • • • • 6 •
Pvs28-V (n = 1) • • • • • • • 6 M
Pvs28-VI (n = 1) • • • • V • • 6 M
Pvs28-VII (n = 1) • L • • • • E 6 •
SS, secretary signal sequence; EGF, epidermal growth factor-like domain; RR, repeat regions, # indicates the number of the GSGGE/D repeats; THR, the C terminal
hydrophobic region.
• indicates identical amino acid residues compared to the Salvador I strain.
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Zhejiang and Hubei isolates [32], but it was very common
in South Asian isolates such as those from Bangladesh
[25], Thailand [15], India [26], and also in Yunnan
isolates.
Among a total of 24 amino acid substitutions in Pvs28
from worldwide isolates, M52L and T140S were the
most common substitutions from different geographic
regions [15,24-26,31]. The amino acid residues L98I and
L116V were very common in South Asia isolates such
as those from Bangladesh [25], Thailand [15], India [26],
and also in Yunnan isolates. The amino acid residue
T65K was not identified in isolates from Yunnan and
South Korea [22], but was common in those from Ban-
gladesh [25], Thailand [33], India [25,26] and Iran [24].
Genetic diversity of pvs25 and pvs28
There were a total of four polymorphic sites that gener-
ated five haplotypes in pvs25. There were a total of 12
polymorphic sites that yielded eight haplotypes in pvs28.
Nucleotide diversity of pvs28 (π = 0.0034 ± 0.0012) was
significantly higher than that of pvs25 (π = 0.0013 ±
0.0009) (p < 0.05) (Table 5).
Discussion
In this study, we assessed the level of genetic diversity of
pvs25 and pvs28 genes in P. vivax isolates from Yunnan
Province, China. A total of four and eight amino acid
substitutions have been identified in Pvs25 and Pvs28,
respectively. Compared with P. vivax isolates from pre-
vious studies conducted in Asia, our results showed that
the majority of the variant amino acids of Pvs25 and
Pvs28 detected in Yunnan isolates were shared with
those reported in isolates from South Asia (Bangladesh,
Thailand and India) [15,25]. Because of its location in
southwest China, Yunnan isolates had mutant residues
characteristic of South Asian isolates, such as mutant
residues E97Q and Q131K in Pvs25, as well as L98I and
L116V in Pvs28. It suggested that some parasite haplo-
types may have different geographic distributions.
One of the major obstacles to the development of an
effective malaria vaccine is the genetic polymorphism of
many of the genes in natural parasite populations that
otherwise would be promising vaccine candidates. A
number of studies have shown that TBVs candidates
have limited polymorphism compared to antigens
expressed in asexual stage parasites [34,35]. Our data
showed that pvs25 (π = 0.0013) had a much lower level
of diversity than P. vivax blood stage proteins DBP (π =
0.0086-0.0184) [36] and MSP1 (π = 0.1193-0.2055) [37].
In addition, compared with P. falciparum sexual stage
proteins pfs25 (π = 0.0035) [34], the lower genetic diver-
sity of pvs25 suggested that genetic polymorphism of
pvs25 was limited in Yunnan isolates. Although the
nucleotide diversity of pvs28 was significantly higher (π
= 0.0034) than that of pvs25, it was still conserved when
compared with the blood stage vaccine candidates.
Table 3 Amino acid variations of Pvs25 among worldwide isolates
SS EGF-1 EGF-2 EGF-3 EGF-4 THR
Country 2 35 38 87 97 130 131 132 137 138 149 170 174 183 196 198 199 Ref.
Sal-I N L M Q E I Q S C A K C E E S S V AAC99769
Iran • • • Q/K E/Q T • • • • • • • • • • • [24]
Mexico • • • Q/K • I/T • • • • • • • • • • • [31]
Brazil • • • K • • • • • • • • • • • • • [23]
Colombia • • • K • • • • • • • • • • • • • [23]
Venezuela • • T K • • • • • • • • • • • • • [23]
Mauritania • • • K • T • • • • • • • • • • • [23]
Turkey • • • K • T • • • • • • • • • • • ABG29073
PNG • • • • • T K R • • N • • • • • • [23]
Nicaragua • • • • • • • • • • • R • • • • • [23]
India • • • • Q T • • • • • • • • • • • [25]
India • • • • E/Q T Q/K • C/W A/G • • E/K E/K S/F S/T V/E [26]
Bangladesh • • • • E/Q T Q/K • • • • • • • • • • [25]
Vietnam • • • • • T • • • • • • • • • • • ABG29072
Indonesia • • • • Q T • • • • • • • • • • • [23]
Thailand • • • • E/Q T Q/K • • • • • • • • • • [15]
N Korea • • • • • T • • • • • • • • • • • [23]
S Korea N/D • • • E/Q T • • • • • • • • • • • [22]
China (ZJ/HB) • • • • E/Q T • • • • • • • • • • • [32]
China (YN) • L/M • • E/Q T Q/K • • • • • • • • • • This study
SS, secretary signal sequence; EGF, EGF-like domain; THR, the C terminal hydrophobic region. Ref: references. ZJ/HB and YN represented isolates from Zhejiang/
Hubei and Yunnan Provinces in China, respectively. • indicates identical amino acid residues compared to the Salvador I strain.
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Table 4 Amino acid variations of Pvs28 among worldwide isolates















































































Sal-I H V M A T V A D G L E V N N L T K G G D G S 6 V I AAC99770
Iran • • L • T/K • • • • • • • • • • S • • • • • • 4-6 • • [24]
Mexico • • L • • • • N • • • • Y • • S • • • • • • 5-6 • • [31]
Bangladesh • • M/L • T/K • • • • L/I • • • N/S L/V T/S K/
R
• • • • • 5-7 • I/
M
[25]
Thailand • • M/L A/V T/K • A/V • G/N L/I E/K V/E • • L/V T/S • • • • • • 5-7 • • [15]
India • • L • K • • • • • • • • • • S • • • • • • 4 • • [25]
India H/T/Y • M/L A/V T/K V/E • • • L/I E/K • • • L/V T/S • • D D/G G/R S/
T
3-6 V/L I/M [26]




• • • 6 • • [22]
China (YN) • V/L M/L • • • • • • L/I E/K • • • L/V T/S • G/E • • • • 5-6 • I/M This study
SS, secretary signal sequence; EGF, EGF-like domain; RR, repeat regions; THR, the C terminal hydrophobic region. Ref.: references. YN represented isolates from Yunnan Provinces in China. • indicates identical amino
acid residues compared to the Salvador I strain.
















Although direct sequencing of the PCR products in our
study might underestimate the genetic diversity of these
two genes, the effect should be minor since our study
areas are malaria hypoendemic and mixed infections
should not be prevalent. The limited diversity of sexual
stage antigens such as P25 and P28 is perhaps attributed
to the expression of these proteins in mosquito stages,
which should avoid immune selection in the humans.
It is very important to evaluate the effect of genetic
polymorphism of Pvs25 and Pvs28 on the efficacy of Sal-I
based TBVs in different malaria epidemiological areas.
The transmission-blocking assays conducted in Thailand
clearly demonstrated that antisera to recombinant Pvs25
and Pvs28 based on the Sal-I strain of P. vivax recognized
corresponding molecules expressed by field-isolated
parasites in Thailand. Our data showed limited genetic
diversity of pvs25 and pvs28 in the Yunnan isolates. The
major amino acid haplotype of Pvs25 from this region
was also shared with that from Thailand isolates, it pro-
vids a good prospect on implication of TBVs in China
malaria areas.
Altogether, our study offers a first glimpse of the
genetic diversity of two TBVs candidate antigens in Yun-
nan Province, China. Yet, this study only offered limited
information of P. vivax parasites from Yunnan. Further
studies on a larger sample scale and comparison analysis
with Central China isolates will certainly improve our
understanding of genetic polymorphisms of TBVs candi-
dates in the malaria endemic areas of China.
Conclusions
TBVs are one of the important strategies for controlling
malaria transmission. A key point in vaccine optimization
is to understand the extent of genetic diversity of candi-
date antigens. The TBVs candidates Pvs25 and Pvs28
from Yunnan isolates showed limited genetic diversity.
Further studies encompassing larger malaria endemic
areas are needed to provide a thorough evaluation of
situation in China.
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